Euprotec Secures £165k Corridor Growth Fund Grant
Specialist contract research organisation (CRO), Euprotec, has been awarded £165,000 from the Corridor Growth Fund (CGF) to fuel its expansion plans, as it broadens its anti-infective drug discovery and development capabilities.
Supported by the Government’s Regional Growth Fund, the £2 million CGF provides grant funding to qualifying applicants, helping to underpin the private sector-led growth of the knowledge economy in Manchester.
The funding will enhance and expand Euprotec’s state-of-the-art microbiology facilities on the Manchester Science Park (MSP). This will allow the company to build upon its bespoke range of R&D services, accelerating the discovery and development of new infectious disease diagnostics, antimicrobial drugs and vaccines.
Euprotec has grown rapidly since its formation in 2008, developing worldwide partnerships with leading pharma and biotech companies as well as government and academic institutions. The grant will provide further support to Euprotec in developing and delivering innovative research solutions to its partners in the strategically vital area of infection.
The government’s chief medical officer, Dame Sally Davies, has recently described antimicrobial resistance as a “ticking time-bomb” and suggested that, if we don't take action, then we may all be back in an almost 19th Century environment where infections kill us as a result of routine operations.
As part of Euprotec’s expansion, the company will also continue to build its comprehensive and highly characterised collection of bacteria and fungi, a resource which is critically important to its clients’ research programmes. This strainbank will enable a continued focus on multidrug resistant pathogens, new testing methodologies, and a greater understanding of mechanisms of resistance.
Lloyd Payne, chief executive of Euprotec, said: “This funding is a boost not only for Euprotec but also for the broader biomedical community based in Manchester and the North West. The investment will enable us to support an even greater number of organisations in the discovery of new anti-infective vaccines and therapies, helping to address the significant challenges and global health issues that have arisen as a result of antimicrobial resistance.”
Sir Richard Leese, leader of Manchester City Council, said: “Manchester has an incredibly strong science and research base and building on that is going to be an important element of the city’s growth. This fund should help incentivise businesses to locate in the Corridor area, attracting further jobs and investment.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance